SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals inches up on getting USFDA’s final approval for Fenofibrate Capsules

21 Oct 2020 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 982.05, up by 0.05 points or 0.01% from its previous closing of Rs. 982.00 on the BSE.

The scrip opened at Rs. 983.95 and has touched a high and low of Rs. 987.75 and Rs. 973.80 respectively. So far 9659 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1128.00 on 07-Aug-2020 and a 52 week low of Rs. 436.10 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 989.00 and Rs. 933.50 respectively. The current market cap of the company is Rs. 19302.50 crore.

The promoters holding in the company stood at 69.77%, while Institutions and Non-Institutions held 16.46% and 13.76% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg.

Fenofibrate Capsules USP, 67 mg, 134 mg and 200 mg have an estimated market size of $17 million for twelve months ending June 2020. Alembic Pharmaceuticals has a cumulative total of 133 ANDA (115final approvals and 18tentaive approval) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

763.55 4.55 (0.60%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×